I tend to go conservative on my evaluations. On COVID approval I still think $15 - $20 is very realistic to where it will settle initially. Which is all of that $10 billion market cap. Between institutional investors shrinking the pool of available shares, catalysts and appreciation by investors of the potential $35 - $40 by end of the year is within the ballpark (still being conservative).